Akeso Doses First Patient in Phase II Study of Novel TROP2/Nectin-4 Bispecific ADC (AK146D1) in Combination with Ivonescimab for Advanced NSCLC

Phase 2AK146D1IvonescimabPositive

AI Analysis

Summary

Akeso announced dosing of the first patient in Phase II trial (AK146D1-201) evaluating its TROP2/Nectin-4 bispecific ADC (AK146D1) combined with ivonescimab for advanced non-small cell lung cancer.

Clinical Trial Data

Phase

Phase II

Outcome Details

First patient dosed in Phase II study

Importance:5/10

Sentiment:

0.50

oncologyNSCLCbispecific ADCcombination therapyclinical trial initiation

Related Companies

$TRAX

Read the original article

Published by PR Newswire Clinical Trials on July 20, 2026 5:32 AM

Read Original